Clinical Trials

55 enrolled

Breast Neoplasms, Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03417544 2025-04-02

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

19 enrolled 26 charts

BreastCNS

HER2-positive Metastatic Breast Cancer

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

240 enrolled

Breast Neoplasms

NCT05498896 2025-03-10

BARBICAN

146 enrolled

Triple Negative Breast Neoplasms

NCT03125928 2025-01-10

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

16 enrolled

HER2-positive Breast Cancer

NCT04819243 2025-01-03

Young-PALETTA

178 enrolled

Premenopausal HR+/HER2- Metastatic Breast Cancer

NCT03164993 2024-10-15

ALICE

68 enrolled

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT06342037 2024-09-19

TONIC-3

60 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03395899 2024-06-18

ECLIPSE

71 enrolled

Breast Neoplasms

NCT04408118 2024-06-04

ATRACTIB

100 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04739670 2024-03-01

BELLA

31 enrolled

Recurrence, Triple Negative Breast Neoplasms

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

49 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04690855 2023-12-04

TARA

1 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03756298 2023-11-09

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

284 enrolled

Triple Negative Breast Neoplasms

NCT04591431 2023-10-03

ROME

BreastGastrointestinalThoracic

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03961698 2023-08-14

MARIO-3

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT02322814 2023-04-13

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

169 enrolled 31 charts

Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03147040 2022-07-19

GELATO

23 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03894007 2021-09-23

PREDIXIIHER2

6 enrolled

Breast Neoplasms

NCT03952325 2021-07-30

CONTESSA TRIO

294 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02924883 2021-02-17

KATE2

202 enrolled 21 charts

Breast Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.